Patents by Inventor Manoj K. Mishra

Manoj K. Mishra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250114319
    Abstract: A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson's disease by administering to a mammal an amount sufficient to treat Parkinson's disease.
    Type: Application
    Filed: June 5, 2024
    Publication date: April 10, 2025
    Applicant: Dynamic Biologics Inc.
    Inventors: Deven Patel, Manoj K Mishra, H Rajan Sharma, Leema Reddy Peddareddy gari
  • Patent number: 12036199
    Abstract: A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson's disease by administering to a mammal an amount sufficient to treat Parkinson's disease.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: July 16, 2024
    Assignee: Dynamic Biologics Inc.
    Inventors: Deven Patel, Manoj K. Mishra, H. Rajan Sharma, Leema Reddy Peddareddy gari
  • Publication number: 20210252153
    Abstract: A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.
    Type: Application
    Filed: February 12, 2021
    Publication date: August 19, 2021
    Inventors: Antonella Mangraviti, Panagiotis Mastorakos, Manoj K. Mishra, Kannan Rangaramanujam, Betty M. Tyler, Fan Zhang
  • Patent number: 10918720
    Abstract: A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: February 16, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Kannan Rangaramanujam, Betty M. Tyler, Fan Zhang, Panagiotis Mastorakos, Manoj K. Mishra, Antonella Mangraviti
  • Publication number: 20190314169
    Abstract: A vertebral disc including a superior surface layer, an inferior surface layer, a midsection between the superior and inferior surface layers and a hollow center. The superior surface layer and inferior surface layer each comprise a layer of lattice with pore sizes in the range of 200-900 ?m and a porosity of each layer of 55-75%. The midsection of the implant comprises a random or pseudorandom lattice interposed between the superior surface layer and inferior surface layer with larger, macro-pores of various sizes. There is a gradient of pore sizes along a longitudinal axis with the smallest pore sizes comprising the superior and inferior surfaces and the largest pore sizes comprising the midsection.
    Type: Application
    Filed: April 15, 2019
    Publication date: October 17, 2019
    Inventors: Amit Patel, Manoj K. Mishra, Deven Patel
  • Publication number: 20170173172
    Abstract: A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.
    Type: Application
    Filed: August 13, 2015
    Publication date: June 22, 2017
    Inventors: Antonella Mangraviti, Panagiotis Mastorakos, Manoj K. Mishra, Kannan Rangaramanujam, Betty M. Tyler, Fan Zhang